New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 17, 2013
05:32 EDTASTXAstex Pharmaceuticals, Cancer Research UK, CRT start AT13148 clinical trial
Astex Pharmaceuticals announced that collaborators Cancer Research UK and its commercial arm Cancer Research Technology, or CRT, are launching a trial of an experimental drug shown to simultaneously block many enzymes that control cancer cell growth and death. The 'master-switch' experimental drug, owned by Astex Pharmaceuticals, is being studied in a range of cancer types. Cancer Research UK's Drug Development Office, or DDO, will fund, manage and sponsor this early-stage Phase I clinical trial of up to 40 patients at The Institute of Cancer Research, London, and The Royal Marsden Hospital. The drug, AT13148, is one of eight drugs to be developed through Cancer Research UK's Clinical Development Partnerships program, which is a joint initiative between the charity's DDO and CRT. The program develops promising cancer drugs that pharmaceutical companies do not have the resources to progress through early phase clinical trials to see if they can benefit cancer patients.
News For ASTX From The Last 14 Days
Check below for free stories on ASTX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for ASTX

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use